Step 9 of 10 · Decision support
Swiss reimbursement
What this step shows
Whether the recommended treatment meets the Swiss reimbursement criteria for this patient — and which criteria are still missing if not.
Risk category
Very High
LDL-C target
<1.4 mmol/L
Treatment plan
Consider PCSK9 inhibitor pathway (e.g. evolocumab / alirocumab)
Reimbursement status
Eligible
All demo reimbursement criteria are met.
Criteria checked
- ✓ LDL-C above the reimbursement threshold despite therapy? Current LDL-C 3 mmol/L vs. threshold 1.4 mmol/L.
- ✓ Documented intolerance to ≥2 statins, on ezetimibe? Rechallenge/alternative statin documented, ezetimibe in place — satisfies the intolerance route.
- ✓ Prescription confirmed/supported by a specialist? Specialist involvement documented.